↓ Skip to main content

Dove Medical Press

Article Metrics

Current status of bevacizumab in advanced ovarian cancer

Overview of attention for article published in OncoTargets and therapy, July 2013
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
19 Mendeley
citeulike
1 CiteULike
Title
Current status of bevacizumab in advanced ovarian cancer
Published in
OncoTargets and therapy, July 2013
DOI 10.2147/ott.s46301
Pubmed ID
Authors

Luigi Rossi, Federica Tomao, Anselmo Papa, David Caruso, Benedetti Panici Pierluigi, Silverio Tomao, Martina Venezia

Abstract

Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible target. The aim of this review is to investigate the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in patients with ovarian cancer. These therapeutic strategies include monoclonal antibodies and tyrosine-kinase inhibitors. These drugs have as molecular targets vascular endothelial growth factor, vascular endothelial growth factor receptors, platelet-derived growth factor, fibroblast growth factor, and angiopoietin. Bevacizumab was investigated in several Phase III studies, with interesting results. Today, there is strong evidence for introducing bevacizumab in the treatment of patients with advanced and recurrent ovarian cancer. Nevertheless, further investigations and large clinical trials are needed to understand the safety and effectiveness of bevacizumab, the optimal duration and timing of treatment, and activity in association with other chemotherapeutic and targeted agents. It also is necessary to identify biologic factors predictive of efficacy to choose the most appropriate antiangiogenic agent in the integrated treatment of epithelial ovarian cancer.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ecuador 2 11%
United States 1 5%
Unknown 16 84%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 42%
Student > Ph. D. Student 4 21%
Other 3 16%
Student > Master 1 5%
Student > Doctoral Student 1 5%
Other 1 5%
Unknown 1 5%
Readers by discipline Count As %
Agricultural and Biological Sciences 7 37%
Medicine and Dentistry 6 32%
Biochemistry, Genetics and Molecular Biology 2 11%
Psychology 1 5%
Unknown 3 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2013.
All research outputs
#2,124,995
of 4,507,509 outputs
Outputs from OncoTargets and therapy
#84
of 401 outputs
Outputs of similar age
#44,001
of 97,739 outputs
Outputs of similar age from OncoTargets and therapy
#5
of 18 outputs
Altmetric has tracked 4,507,509 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 401 research outputs from this source. They receive a mean Attention Score of 1.3. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 97,739 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.